Aduro Biotech, Inc. announced that Aimee Luck Murphy has been promoted to the position of vice president of clinical development and operations. Ms. Murphy began consulting for Aduro on the LADD program in 2009. She joined Aduro as director of clinical operations in 2011 and was promoted to senior director of clinical development and operations in 2013.

Prior to Aduro, Ms. Murphy advanced the development of the LADD platform at both Cerus Corporation and Anza Therapeutics, where she managed the first Phase 1 studies to support what are now Aduro's LADD clinical programs. Prior to working on LADD, she developed prophylactic vaccines and drugs for oncology and infectious diseases at VaxGen, Coulter Pharmaceuticals, and Shaman Pharmaceuticals. Additionally, Ms. Murphy brings experience in quality assurance from Bayer Pharmaceuticals.